表紙
市場調査レポート

Lipicard Technologies Limited:製品パイプライン分析

Lipicard Technologies Limited - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 306628
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
Lipicard Technologies Limited:製品パイプライン分析 Lipicard Technologies Limited - Product Pipeline Review - 2015
出版日: 2015年05月20日 ページ情報: 英文 58 Pages
概要

当レポートでは、Lipicard Technologies Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Lipicard Technologies Limitedの基本情報

Lipicard Technologies Limitedの概要

  • 主要情報
  • 企業情報

Lipicard Technologies Limited:R&Dの概要

  • 主な治療範囲

Lipicard Technologies Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Lipicard Technologies Limited:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Lipicard Technologies Limited:薬剤プロファイル

  • Gabafol
  • KeraKlear
  • LT-1121
  • LT-1123
  • LT-2121
  • LT-2221
  • LT-2223
  • LT-2321
  • LT-2322
  • LT-2323
  • LT-2421
  • LT-2423
  • LT-2521
  • LT-3121
  • LT-3122
  • LT-4121
  • LT-4122
  • LT-4123
  • LT-4124
  • LT-4125
  • LT-4126
  • LT-5121
  • LT-5122
  • LT-5221
  • LT-5222
  • LT-5223
  • LT-5321
  • LT-5322
  • LT-5323
  • LT-5421
  • LT-5423
  • LT-6121
  • Peroxibrate
  • Platrol
  • Raviprofen

Lipicard Technologies Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Lipicard Technologies Limited:休止中のプロジェクト

Lipicard Technologies Limited:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07045CDB

Summary

Global Markets Direct's, 'Lipicard Technologies Limited - Product Pipeline Review - 2015', provides an overview of the Lipicard Technologies Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lipicard Technologies Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Lipicard Technologies Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Lipicard Technologies Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Lipicard Technologies Limited's pipeline products

Reasons to buy

  • Evaluate Lipicard Technologies Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Lipicard Technologies Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Lipicard Technologies Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Lipicard Technologies Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lipicard Technologies Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Lipicard Technologies Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lipicard Technologies Limited Snapshot
    • Lipicard Technologies Limited Overview
    • Key Information
    • Key Facts
  • Lipicard Technologies Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Lipicard Technologies Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Lipicard Technologies Limited - Pipeline Products Glance
    • Lipicard Technologies Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Lipicard Technologies Limited - Drug Profiles
    • Gabafol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KeraKlear
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-1121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-1123
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2221
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2223
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2321
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2322
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2323
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2421
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2423
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2521
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-3121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-3122
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4122
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4123
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4124
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4125
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4126
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5122
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5221
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5222
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5223
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5321
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5322
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5323
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5421
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5423
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5521
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peroxibrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Platrol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Raviprofen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-6121
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lipicard Technologies Limited - Pipeline Analysis
  • Lipicard Technologies Limited - Pipeline Products by Target
  • Lipicard Technologies Limited - Pipeline Products by Route of Administration
  • Lipicard Technologies Limited - Pipeline Products by Molecule Type
  • Lipicard Technologies Limited - Pipeline Products by Mechanism of Action
  • Lipicard Technologies Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lipicard Technologies Limited, Key Information
  • Lipicard Technologies Limited, Key Facts
  • Lipicard Technologies Limited - Pipeline by Indication, 2015
  • Lipicard Technologies Limited - Pipeline by Stage of Development, 2015
  • Lipicard Technologies Limited - Monotherapy Products in Pipeline, 2015
  • Lipicard Technologies Limited - Preclinical, 2015
  • Lipicard Technologies Limited - Discovery, 2015
  • Lipicard Technologies Limited - Pipeline by Target, 2015
  • Lipicard Technologies Limited - Pipeline by Route of Administration, 2015
  • Lipicard Technologies Limited - Pipeline by Molecule Type, 2015
  • Lipicard Technologies Limited - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Lipicard Technologies Limited - Pipeline by Top 10 Indication, 2015
  • Lipicard Technologies Limited - Pipeline by Stage of Development, 2015
  • Lipicard Technologies Limited - Monotherapy Products in Pipeline, 2015
  • Lipicard Technologies Limited - Pipeline by Top 10 Target, 2015
  • Lipicard Technologies Limited - Pipeline by Top 10 Route of Administration, 2015
  • Lipicard Technologies Limited - Pipeline by Top 10 Molecule Type, 2015
  • Lipicard Technologies Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top